We are live on ! Find out more
RNAC icon

Cartesian Therapeutics

46 hedge funds and large institutions have $124M invested in Cartesian Therapeutics in 2017 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 14 increasing their positions, 7 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

175% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 4

100% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 7

7% more funds holding

Funds holding: 4346 (+3)

0.06% more ownership

Funds ownership: 1.5%1.56% (+0.06%)

12% less capital invested

Capital invested by funds: $140M → $124M (-$16.7M)

33% less funds holding in top 10

Funds holding in top 10: 32 (-1)

Holders
46
Holders Change
+3
Holders Change %
+6.98%
% of All Funds
1.15%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.05%
New
11
Increased
14
Reduced
7
Closed
4
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
PVMCV
1
Polaris Venture Management Co V
Massachusetts
$27.6M
O
2
OrbiMed
New York
$26.4M
DM
3
Deerfield Management
New York
$15.2M +$2.9M +6,893 +24%
FP
4
Flagship Pioneering
Massachusetts
$11.8M
SRF
5
Silver Rock Financial
California
$9.68M +$3.03M +7,199 +47%
Fidelity Investments
6
Fidelity Investments
Massachusetts
$4.09M
JP Morgan Chase
7
JP Morgan Chase
New York
$3.5M -$221K -525 -6%
Millennium Management
8
Millennium Management
New York
$3.4M +$1.61M +3,835 +94%
SFM
9
Sphera Funds Management
Israel
$3.27M -$561K -1,333 -15%
BlackRock
10
BlackRock
New York
$2.99M +$2.92M +6,947 +115,783%
BBA
11
Baker Bros. Advisors
New York
$2.52M
T. Rowe Price Associates
12
T. Rowe Price Associates
Maryland
$2.18M -$1.35M -3,200 -39%
PA
13
Perceptive Advisors
New York
$2.03M
Vanguard Group
14
Vanguard Group
Pennsylvania
$1.13M +$157K +372 +16%
HLA
15
Hamilton Lane Advisors
Pennsylvania
$1.07M
WA
16
Wasatch Advisors
Utah
$1.07M -$842 -2 -0.1%
UBS Group
17
UBS Group
Switzerland
$1.02M +$925K +2,198 +1,214%
State Street
18
State Street
Massachusetts
$997K +$1.68K +4 +0.2%
Geode Capital Management
19
Geode Capital Management
Massachusetts
$708K +$39.1K +93 +6%
Northern Trust
20
Northern Trust
Illinois
$566K +$35.3K +84 +7%
Goldman Sachs
21
Goldman Sachs
New York
$452K +$201K +478 +83%
CS
22
Candriam SCA
Luxembourg
$444K +$435K +1,033 New
HP
23
Hikari Power
Japan
$349K +$342K +812 New
Bank of New York Mellon
24
Bank of New York Mellon
New York
$211K +$207K +491 New
Susquehanna International Group
25
Susquehanna International Group
Pennsylvania
$192K +$188K +447 New

RNAC Hedge Fund Activity: Q1 2017 in Review

46 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q1 2017, worth a combined $124M — down 12% from $140M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new RNAC positions and 4 closed out — a net gain of 7 holders — while 14 added to existing stakes and 7 trimmed.

The largest buyer was Silver Rock Financial, adding an estimated $3.03M. The largest seller was State of Michigan Retirement System, exiting entirely with an estimated $1.65M sold.

  • 46 institutional investors held Cartesian Therapeutics (RNAC) as of Q1 2017, up from 43 in Q4 2016.
  • Funds reported $124M of Cartesian Therapeutics stock for Q1 2017, down 12% quarter-over-quarter.
  • 11 funds opened new Cartesian Therapeutics positions in Q1 2017 and 4 closed out, a net change of +7 holders.
  • The largest Cartesian Therapeutics buyer in Q1 2017 was Silver Rock Financial, an estimated $3.03M added.
  • The largest Cartesian Therapeutics seller in Q1 2017 was State of Michigan Retirement System, an estimated $1.65M sold.

Based on aggregated 13F filings for Q1 2017.